- Recipharm forms strategic alliance with Exela Pharma Sciences to expand sterile manufacturing capabilities in the US, including 100 million units of vial and pre-filled syringe production.
- The collaboration includes advanced biopharmaceutical manufacturing, covering ADCs, GLP-1 drugs, and vaccines.
Recipharm, a contract development and manufacturing organisation (CDMO), has entered into a strategic alliance with US-based Exela Pharma Sciences. Announced on 1st October 2024, the partnership aims to enhance sterile manufacturing capabilities in the United States. This collaboration provides Recipharm access to Exela’s FDA-accredited facility in Lenoir, North Carolina, with a production capacity exceeding 100 million units annually for vials and pre-filled syringes (PFS).
The alliance strengthens Recipharm’s presence in sterile injectable pharmaceuticals, allowing expansion into highly specialised products, including Antibody Drug Conjugates (ADCs) and GLP-1 drugs. Exela’s automated manufacturing processes and auto-injector assembly add further efficiencies to the operation.
The Lenoir site, recognised for its swift response during the COVID-19 pandemic, will also adhere to Recipharm’s international compliance standards, enhancing services for both US and global pharmaceutical markets.
Greg Behar, CEO of Recipharm, expressed his enthusiasm for the partnership: “We are excited about this strategic alliance with Exela, which significantly enhances our manufacturing footprint in the US.” Phanesh Koneru, CEO of Exela, highlighted the collaboration’s potential for biopharma customers in both US and EU markets.
 Overview of outsourcing trends 
